Precision sniper for solid tumors: CAR-NK cell therapy
Abstract Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-025-04106-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849332836305207296 |
|---|---|
| author | Sisi Li Jiajie Jing Yueming Chen Enjie Chi Bingyan Wang Ziwen Xie Wenya Yang Hongqiang Shen Jianping Pan |
| author_facet | Sisi Li Jiajie Jing Yueming Chen Enjie Chi Bingyan Wang Ziwen Xie Wenya Yang Hongqiang Shen Jianping Pan |
| author_sort | Sisi Li |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in treating hematologic malignancies. However, its efficacy against solid tumors remains inadequate and is accompanied by toxic side effects, including cytokine release syndrome, neurotoxicity and on-target/off-tumor effects. In contrast to T cells, natural killer (NK) cells exhibit a broader source range and can non-specifically lyse tumor cells. Moreover, it can also reduce toxicity and side effects to some extent. This review comprehensively examines recent research progress on CAR-NK therapy for solid tumors, encompassing both in vivo and in vitro studies, with a focus on CAR-NK cell design and production methods. Drawing upon laboratory and clinical evidence, this review summarizes the current challenges and side effects associated with CAR-NK technology. |
| format | Article |
| id | doaj-art-b6f4c2e0e4dd4a58bb9d819ee6ec942b |
| institution | Kabale University |
| issn | 1432-0851 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Springer |
| record_format | Article |
| series | Cancer Immunology, Immunotherapy |
| spelling | doaj-art-b6f4c2e0e4dd4a58bb9d819ee6ec942b2025-08-20T03:46:04ZengSpringerCancer Immunology, Immunotherapy1432-08512025-07-0174912210.1007/s00262-025-04106-zPrecision sniper for solid tumors: CAR-NK cell therapySisi Li0Jiajie Jing1Yueming Chen2Enjie Chi3Bingyan Wang4Ziwen Xie5Wenya Yang6Hongqiang Shen7Jianping Pan8Department of Clinical Medicine, Hangzhou City University School of MedicineDepartment of Clinical Medicine, Hangzhou City University School of MedicineDepartment of Clinical Medicine, Hangzhou City University School of MedicineDepartment of Clinical Medicine, Hangzhou City University School of MedicineDepartment of Clinical Medicine, Hangzhou City University School of MedicineDepartment of Clinical Medicine, Hangzhou City University School of MedicineDepartment of Clinical Medicine, Hangzhou City University School of MedicineDepartment of Clinical Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child HealthDepartment of Clinical Medicine, Hangzhou City University School of MedicineAbstract Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in treating hematologic malignancies. However, its efficacy against solid tumors remains inadequate and is accompanied by toxic side effects, including cytokine release syndrome, neurotoxicity and on-target/off-tumor effects. In contrast to T cells, natural killer (NK) cells exhibit a broader source range and can non-specifically lyse tumor cells. Moreover, it can also reduce toxicity and side effects to some extent. This review comprehensively examines recent research progress on CAR-NK therapy for solid tumors, encompassing both in vivo and in vitro studies, with a focus on CAR-NK cell design and production methods. Drawing upon laboratory and clinical evidence, this review summarizes the current challenges and side effects associated with CAR-NK technology.https://doi.org/10.1007/s00262-025-04106-zSolid tumorsImmunotherapyCAR-NKTargeted therapy |
| spellingShingle | Sisi Li Jiajie Jing Yueming Chen Enjie Chi Bingyan Wang Ziwen Xie Wenya Yang Hongqiang Shen Jianping Pan Precision sniper for solid tumors: CAR-NK cell therapy Cancer Immunology, Immunotherapy Solid tumors Immunotherapy CAR-NK Targeted therapy |
| title | Precision sniper for solid tumors: CAR-NK cell therapy |
| title_full | Precision sniper for solid tumors: CAR-NK cell therapy |
| title_fullStr | Precision sniper for solid tumors: CAR-NK cell therapy |
| title_full_unstemmed | Precision sniper for solid tumors: CAR-NK cell therapy |
| title_short | Precision sniper for solid tumors: CAR-NK cell therapy |
| title_sort | precision sniper for solid tumors car nk cell therapy |
| topic | Solid tumors Immunotherapy CAR-NK Targeted therapy |
| url | https://doi.org/10.1007/s00262-025-04106-z |
| work_keys_str_mv | AT sisili precisionsniperforsolidtumorscarnkcelltherapy AT jiajiejing precisionsniperforsolidtumorscarnkcelltherapy AT yuemingchen precisionsniperforsolidtumorscarnkcelltherapy AT enjiechi precisionsniperforsolidtumorscarnkcelltherapy AT bingyanwang precisionsniperforsolidtumorscarnkcelltherapy AT ziwenxie precisionsniperforsolidtumorscarnkcelltherapy AT wenyayang precisionsniperforsolidtumorscarnkcelltherapy AT hongqiangshen precisionsniperforsolidtumorscarnkcelltherapy AT jianpingpan precisionsniperforsolidtumorscarnkcelltherapy |